Navigation Links
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Date:8/27/2012

l Trials, (%), 2000-2010 33Figure 7: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 35Figure 8: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 37Figure 9: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 39Figure 10: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 40Figure 11: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 41Figure 12: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 43Figure 13: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 45Figure 14: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 47Figure 15: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 49Figure 16: Endpoints – Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 50Figure 17: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Total Number of Clinical Trials, 2000-2010 76Figure 18: Endpoints – Clinical Trials in Respiratory Disorders, COPD, Global, Phase of Clinical Trials, 2000-2010 77Figure 19: Endpoints –
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
2. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
5. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
6. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
7. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
9. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
10. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... our Medicare resources and continue highlighting the success of the prescription drug benefit, commonly ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Inc. (NYSE: WPI ) today announced that ... with Endo Pharmaceuticals, Inc. on outstanding patent litigation related ... its lawsuit on March 4, 2010, following Watson,s filing ... U.S. Food and Drug Administration (FDA) for seeking approval ...
... Inc. (Nasdaq: AKRX ) will host a conference ... results followed by a Q&A session.  The company will release ... Akorn Third Quarter 2010 Conference CallDate/Time: , Tuesday, November ... (888) 215-6895International Callers: , (913) 312-0860Confirmation Code: , ...
Cached Medicine Technology:Watson Reaches Settlement with Endo Over Opana® ER 2
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... message including ones already sent. , While text messaging has more features than it ...
(Date:7/31/2015)... York, New York (PRWEB) , ... July 31, 2015 , ... ... to strut their stuff, Super-Sod debuted their new type of sod called Leisure ... registered trademark application in process. , To commemorate introduction of this new type of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Precision Aesthetics is ... years. It was also the first provider of Exilis non-surgical fat reduction in ... after procedures it has attracted a large International clientele. Many patients travel to ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Study Defining Mechanism,and Potential Treatment for Rett Syndrome, Leading ... trial to test molecule in humans is being planned ... to other forms of autism - , BOSTON ... research, clinical and family collaboration dedicated to radically accelerating ...
... 9 Immtech Pharmaceuticals, Inc. (NYSE Alternext: IMM) today ... 31, 2008.For the three months ended December 31, 2008, ... three months ended December 31, 2007. The decrease ... a research and testing agreement. Loss from operations ...
... The Emergency Nurses Association (ENA) today announced the corporate sponsors ... Nevada on March 4 - 8, 2009.This year,s sponsors are ... pleased that these two companies have chosen to support emergency ... ENA Leadership Conference," said William T. Briggs, RN, MSN, CEN, ...
... ANN ARBOR, Mich., Feb. 9 A research brief ... percent of children used,health services due to influenza-like illness ... than double the rate for adults. , ... children used healthcare,services for ILI than families without children ...
... of cardiovascular disease, cancer , , MONDAY, Feb. 9 (HealthDay ... supplement industry, researchers find no evidence that multivitamin use ... the top two killers of women, respectively. , "Women ... seem to do no harm, but they also seem ...
... & IVF Institute,s New SALUTE(TM) Program Honors Military FAIRFAX, Va., ... that it is offering special discounts on in vitro fertilization ... of the military who retired after at least twenty years ... a 25% per cycle discount on single cycles of in ...
Cached Medicine News:Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 2Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 3Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 2Health News:Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study 2Health News:Vitamins Do Older Women Little Good 2Health News:Vitamins Do Older Women Little Good 3Health News:Special Discounts On Fertility Treatment For Active Duty and Retired Military 2
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: